FDA approves aprocitentan (Tryvio) for treatment-resistant hypertension

Aprocitentan (Tryvio), an endothelin receptor antagonist, is indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower BP in adult patients who are not adequately controlled on other drugs. Efficacy and safety were evaluated in the phase 3 PRECISION study involving 730 adults with systolic BP ≥140 mm Hg despite use of at least three antihypertensive medications. The recommended dosage of aprocitentan is 12.5 mg orally once daily, with or without food.